Brief reports
Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban

https://doi.org/10.1016/S0002-9149(02)02892-8Get rights and content

Section snippets

Acknowledgements

We thank Barbara McVan, RN, Patricia Q. Baumann, MS, Michaeleanne Rowen, RN, Danielle C. Tardiff, RN, Shiv Kapoor, PhD, Jaromir Bobek, MS, Debbie Regan, RN, and Cyndi Dietrich, MS, without whom completion of the studies would not be possible.

First page preview

First page preview
Click to open first page preview

Cited by (70)

  • Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series

    2018, Cardiovascular Revascularization Medicine
    Citation Excerpt :

    These studies demonstrated an acceptable 30-day safety profile between the IC and IV routes of administration. In the majority of these cases, the 10 mcg/kg bolus was used, which has been proven to provide inadequate platelet aggregation inhibition [36,37]. There are only three randomized control studies investigating the use of the current FDA-recommended high dose bolus (HDB) regimen of 25 mcg/kg tirofiban.

View all citing articles on Scopus

This study was supported by Merck & Company, Inc., West Point, Pennsylvania.

View full text